Forte Biosciences annual ebitda
2015
2016
2017
2018
2019
2020
2021
2023
2024
2025
Forte Biosciences EBITDA Growth & History (FBRX)
Forte Biosciences's calculated EBITDA was −$70.6M for fiscal 2025.
View full Forte Biosciences company overviewForte Biosciences annual ebitda history
| Fiscal year | Period ended | EBITDA | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −$70.6M | −$34.0M | — |
| 2024 | 2024-12-31 | −$36.6M | −$4.1M | — |
| 2023 | 2023-12-31 | −$32.5M | −$11.0M | — |
| 2021 | 2021-12-31 | −$21.4M | $24.8M | — |
| 2020 | 2020-12-31 | −$46.2M | −$42.2M | — |
| 2019 | 2019-12-31 | −$4.1M | $41.2M | — |
| 2018 | 2018-12-31 | −$45.2M | −$7.9M | — |
| 2017 | 2017-12-31 | −$37.3M | −$5.9M | — |
| 2016 | 2016-12-31 | −$31.4M | −$8.7M | — |
| 2015 | 2015-12-31 | −$22.7M | — | — |
Forte Biosciences quarterly ebitda
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$24.6M | −$13.0M | — |
| Q1 2026 | 2026-03-31 | −$22.4M | −$6.3M | — |
| Q4 2025 | 2025-12-31 | −$24.6M | −$17.2M | — |
| Q3 2025 | 2025-09-30 | −$18.4M | −$9.7M | — |
| Q2 2025 | 2025-06-30 | −$11.6M | $1.2M | — |
| Q1 2025 | 2025-03-31 | −$16.1M | −$8.3M | — |
| Q4 2024 | 2024-12-31 | −$7.3M | −$4.0M | — |
| Q3 2024 | 2024-09-30 | −$8.6M | −$929,000 | — |
| Q2 2024 | 2024-06-30 | −$12.8M | −$7.1M | — |
| Q1 2024 | 2024-03-31 | −$7.8M | −$3.1M | — |
| Q4 2021 | 2021-12-31 | −$3.3M | $1.2M | — |
| Q3 2021 | 2021-09-30 | −$7.7M | −$2.7M | — |
| Q2 2021 | 2021-06-30 | −$5.7M | $29.0M | — |
| Q1 2021 | 2021-03-31 | −$4.7M | −$2.7M | — |
| Q4 2020 | 2020-12-31 | −$4.5M | −$18.0M | — |
| Q3 2020 | 2020-09-30 | −$5.0M | −$4.5M | — |
| Q2 2020 | 2020-06-30 | −$34.7M | −$34.3M | — |
| Q1 2020 | 2020-03-31 | −$2.0M | $14.6M | — |
| Q4 2019 | 2019-12-31 | $13.5M | $32.4M | — |
| Q3 2019 | 2019-09-30 | −$460,000 | −$2.1M | — |
| Q2 2019 | 2019-06-30 | −$412,000 | $14.8M | — |
| Q1 2019 | 2019-03-31 | −$16.7M | −$3.9M | — |
| Q4 2018 | 2018-12-31 | −$18.9M | −$8.3M | — |
| Q3 2018 | 2018-09-30 | $1.6M | $11.3M | — |
| Q2 2018 | 2018-06-30 | −$15.2M | −$6.6M | — |
| Q1 2018 | 2018-03-31 | −$12.8M | −$4.3M | — |
| Q4 2017 | 2017-12-31 | −$10.6M | −$2.7M | — |
| Q3 2017 | 2017-09-30 | −$9.7M | −$1.2M | — |
| Q2 2017 | 2017-06-30 | −$8.6M | −$1.0M | — |
| Q1 2017 | 2017-03-31 | −$8.5M | −$982,000 | — |
| Q4 2016 | 2016-12-31 | −$7.9M | — | — |
| Q3 2016 | 2016-09-30 | −$8.5M | — | — |
| Q2 2016 | 2016-06-30 | −$7.6M | — | — |
| Q1 2016 | 2016-03-31 | −$7.5M | — | — |
Forte Biosciences ebitda trends
Over the last five reported fiscal years, Forte Biosciences's ebitda decreased from −$4.1M to −$70.6M, a change of −$66.5M. The latest reported quarter, Q2 2026, shows −$24.6M.
About the metric
What EBITDA means
EBITDA is a measure of operating performance before interest, taxes, depreciation, and amortization. It can help compare operating results, but it is not a substitute for cash flow or GAAP net income.
Calculation and source
How TickerStat calculates EBITDA
TickerStat calculates EBITDA as operating income plus reported depreciation and amortization for aligned fiscal periods. It is calculated data, not adjusted EBITDA or company guidance. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Forte Biosciences filings at SEC.gov ↗